Adverum Biotechnologies Inc (ADVM) - Total Assets
Based on the latest financial reports, Adverum Biotechnologies Inc (ADVM) holds total assets worth $72.40 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ADVM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Adverum Biotechnologies Inc - Total Assets Trend (2012–2024)
This chart illustrates how Adverum Biotechnologies Inc's total assets have evolved over time, based on quarterly financial data. Check how tangible is Adverum Biotechnologies Inc's equity to evaluate the tangible quality of the company's equity base.
Adverum Biotechnologies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Adverum Biotechnologies Inc's total assets of $72.40 Million consist of 73.0% current assets and 27.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Adverum Biotechnologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ADVM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adverum Biotechnologies Inc's current assets represent 73.0% of total assets in 2024, a decrease from 99.0% in 2012.
- Cash Position: Cash and equivalents constituted 33.7% of total assets in 2024, down from 92.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Adverum Biotechnologies Inc Competitors by Total Assets
Key competitors of Adverum Biotechnologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Adverum Biotechnologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 5.82 | 20.82 |
| Quick Ratio | 0.65 | 5.82 | 20.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-15.84 Million | $133.42 Million | $413.57 Million |
Adverum Biotechnologies Inc - Advanced Valuation Insights
This section examines the relationship between Adverum Biotechnologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | 15.5% |
| Total Assets | $179.84 Million |
| Market Capitalization | $96.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adverum Biotechnologies Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Adverum Biotechnologies Inc's assets grew by 15.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Adverum Biotechnologies Inc (2012–2024)
The table below shows the annual total assets of Adverum Biotechnologies Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $179.84 Million | +15.45% |
| 2023-12-31 | $155.77 Million | -49.49% |
| 2022-12-31 | $308.37 Million | -29.87% |
| 2021-12-31 | $439.73 Million | -8.88% |
| 2020-12-31 | $482.57 Million | +116.66% |
| 2019-12-31 | $222.73 Million | +4.32% |
| 2018-12-31 | $213.50 Million | +5.74% |
| 2017-12-31 | $201.91 Million | -13.93% |
| 2016-12-31 | $234.58 Million | -11.25% |
| 2015-12-31 | $264.32 Million | +63.25% |
| 2014-12-31 | $161.91 Million | +14822.21% |
| 2013-12-31 | $1.08 Million | +181.09% |
| 2012-12-31 | $386.00K | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more